Antibody inhibitors of IL-38 and methods of use thereof for treating or reducing the likelihood of cancer in a subject

Patent metadata

Field	Value
Publication number	US-11427630-B2
Application number	US-201816612723-A
Country	US
Kind code	B2
Filing date	May 7, 2018
Priority date	May 9, 2017
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.

First claim

What is claimed is:

1. An inhibitor of IL-38 for treating and/or reducing a likelihood of occurrence of cancer in a subject, wherein said inhibitor comprises an antibody comprising complementarity determining regions (CDRs) as shown in SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9 or CDRs as shown in SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID N: 12, SEQ ID NO: 13 and SEQ ID NO: 14, wherein the inhibitor further comprises an amino acid sequence SAS.

2. The inhibitor of IL-38 of claim 1 , wherein said antibody is a monoclonal antibody.

3. A pharmaceutical composition comprising an inhibitor of IL-38 according to claim 1 .

4. The pharmaceutical composition of claim 3 , wherein said antibody is a monoclonal antibody.

5. The pharmaceutical composition of claim 3 , further comprising a pharmaceutically acceptable carrier.

6. A method for treating and/or reducing a likelihood of occurrence of cancer in a subject in need thereof comprising administering to said subject an inhibitor of IL-38 according to claim 1 in a therapeutically effective amount.

7. The method of claim 6 , wherein said inhibitor causes deregulation of the tumor-associated immune system.

8. The method of claim 7 , wherein said deregulation of the tumor-associated immune system is characterized by an increase in anti-tumor immune cell populations and/or an increase of pro-inflammatory cytokines.

9. The method of claim 8 , wherein said anti-tumor immune cell population comprises γδ-T cells, wherein said γδ-T cells express the IL-1 receptor accessory protein-like 1 (IL1RAPL1).

10. The method of claim 6 , wherein said inhibitor prevents interaction of IL-38 and the IL-36 receptor (IL1R6) and/or the IL-1 receptor accessory protein-like 1 (IL1RAPL1).

11. The method of claim 6 , wherein said cancer is breast cancer.

12. The method of claim 6 , wherein said subject is a mammal, preferably a human.

13. The method of claim 6 , wherein the inhibitor is given to said subject by parental and/or oral administration.

Assignees

• Fraunhofer Ges Forschung

Inventors

• Weigert Andreas
• Mora Javier
• Brüne Bernhard
• Putyrski Mateusz
• Parnham Michael John
• Ernst Andreas

Classifications

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61P35/00

  Antineoplastic agents · CPC title